Teilnehmen oder Boykottieren: ein Anwendungsbeispiel der binären logistischen Regression mit SPSSx

Da bei einer dichotom abhängigen Variablen die Anwendung des linearen Regressionsmodells oft nicht angemessen ist, schlagen die Autoren als Alternative die Anwendung der logistischen Regression mit Maximum-Likelihood-Schätzung der Modellparameter vor. Am 'Beispiel aus der Begleituntersuchung zur Volkszählung (wird) demonstriert, wie solche Schätzungen interpretiert werden können'. Es geht um die affektive und instrumentelle Einstellung zur Volkszählung 1987 als Prädiktoren der Boykottabsicht. Das Grundkonzept der binären logistischen Regression, Tests der Effekte und Interpretation der Resultate werden ausführlich diskutiert. Analogien zur linearen Regression werden ebenso aufgezeigt wie Unterschiede. Im Anhang wird beispielhaft auf die Vorgehensweise bei einer Analyse mit SPSSx eingegangen. (AG

NOD2 regulates hematopoietic cell function during graft-versus-host disease

Nucleotide-binding oligomerization domain 2 (NOD2) polymorphisms are independent risk factors for Crohn's disease and graft-versus-host disease (GVHD). In Crohn's disease, the proinflammatory state resulting from NOD2 mutations have been associated with a loss of antibacterial function of enterocytes such as paneth cells. NOD2 has not been studied in experimental allogeneic bone marrow transplantation (allo-BMT). Using chimeric recipients with NOD2−/− hematopoietic cells, we demonstrate that NOD2 deficiency in host hematopoietic cells exacerbates GVHD. We found that proliferation and activation of donor T cells was enhanced in NOD-deficient allo-BMT recipients, suggesting that NOD2 plays a role in the regulation of host antigen-presenting cells (APCs). Next, we used bone marrow chimeras in an experimental colitis model and observed again that NOD2 deficiency in the hematopoietic cells results in increased intestinal inflammation. We conclude that NOD2 regulates the development of GVHD through its inhibitory effect on host APC function

Secondary eyewall formation in two idealized, full-physics modeled hurricanes

Atmospheres, 113, D12112, 18 pp.The article of record as published may be located at http://dx.doi.org/10.1029/2007JD00889

Einkommensanalysen mit unterschiedlich differenzierten Klasseneinteilungen

SIGLEBibliothek Weltwirtschaft Kiel C125,947 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman

Das VASMA-Projekt (Vergleichende Analysen der Sozialstruktur mit Massendaten) Ergebnisse und Erfahrungen. Abschlussbericht

SIGLEBibliothek Weltwirtschaft Kiel A156,858 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer

Background Tumour shrinkage (TS) increases the possibility of resection in metastatic colorectal cancer (mCRC) and may improve tumour-related symptoms. Here we report prespecified secondary response-related end-points and exploratory TS/resection outcomes for patients with RAS wild-type (WT) tumours (no mutations in KRAS/NRAS exons 2/3/4) from the PRIME study (NCT00364013). Methods PRIME was a randomised phase 3 study comparing first-line panitumumab + FOLFOX4 versus FOLFOX4 in mCRC patients. Tumour response analyses were conducted to compare response rates and their impact on survival outcomes. Results Overall, 505 patients had RAS WT mCRC. More patients receiving panitumumab + FOLFOX4 versus FOLFOX4 had 6530% (59% versus 38%; P < 0.001) or 6520% (72% versus 57%; P < 0.001) TS at week 8 (early TS); consistent TS benefits were observed over the first 3c40 weeks of treatment. Objective response rate (P = 0.003), duration of response (P = 0.0027), depth of response (P = 0.0149), progression-free survival (PFS; P = 0.0015) and overall survival (OS; P = 0.0057) were improved in the panitumumab + FOLFOX4 group. Both early TS and resection were associated with improved PFS and OS. 2-year OS rates for patients who did (n = 64) versus did not (n = 441) undergo resection were 88% versus 40%; 2-year OS rates for patients who did (n = 45) versus did not (n = 460) undergo complete resection were 96% versus 41%. Conclusions More patients receiving panitumumab + FOLFOX4 versus FOLFOX4 had 6530% or 6520% TS at week 8; PFS and OS were also improved with panitumumab + FOLFOX4. The clinical value of achieving early TS in mCRC warrants further investigation